Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dupilumab in Localized High-Risk Prostate Cancer
NCT03886493Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2019; status: terminated.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03886493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886493.